According to CNN Business writer Hanna Ziady, on February 24, 2020, The Wall Street Journal was the first to report that biotech company Moderna announces they have a first Coronavirus Vaccine ready for testing.

The Cambridge, Massachusetts-based company thus becomes the first company to enter clinical trials with something that, as the Boston Globe reported, “could prevent the disease that has stoked fears and rattled financial markets worldwide.”

According to a February 28, 2020 Boston Globe article reported by Jonathan Saltzman, it took the company just 42 days to develop their trial vaccine.

Better yet, as reported by CNN’s Ziady, “this first batch of its novel coronavirus vaccine, called mRNA-1273, has been sent to the National Institute of Allergy and Infectious Diseases (NIAID)” so that testing can begin.

But don’t hold your breath or rush to your pharmacy to sign up to receive the vaccine. Testing will  begin in April and will be ongoing for at least a year.

Meanwhile, if you’re interested in how this news impacted the company’s stock or the markets in general, which have been in a scary freewill, we refer you to this article by Ben Winck, which we found at Business Insider.

Winck also notes that Moderna is not the only biotech company working on a coronavirus vaccine. On February 26, 2020, fellow biotech company Gilead Sciences, Inc. (Nasdaq: GILD) of California, announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus).

Per Gilead’s press release, “These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March.”